Niagen Bioscience vs Natural Alternatives International
NAGE and NAII side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NAGE and NAII compare
Niagen Bioscience is the larger company, worth 7.4 times as much as Natural Alternatives International ($159M against $21.4M).
Natural Alternatives International grew revenue faster over the last twelve months (9.7% versus −1.9% for Niagen Bioscience).
Niagen Bioscience keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with −14.5% at Natural Alternatives International.
Niagen Bioscience scores higher on the StockData Score (14 against 6 for Natural Alternatives International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NAGE | NAII |
|---|---|---|
| Size and price | ||
| Market cap | $159M | $21.4M |
| Share price | $2.01 | $0.970 |
| Change, 1 year | −71.2% | −71.1% |
| Change, 5 years | −59.1% | −92.6% |
| Beta (5Y) | 1.08 | 0.01 |
| Employees | 117 | 219 |
| StockData Score | ||
| Total score | 14 (better) | 6 |
| Valuation score | 3 (better) | 1 |
| Growth score | 1 | 1 |
| Performance score | 4 (better) | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 16.8× | – |
| P/S | 1.3× | 0.2× (better) |
| P/B | 1.9× | 0.4× (better) |
| EV/EBITDA | 18.8× | – |
| FCF yield | – | −58.8% |
| Fair value | $2.30 | – |
| Margin of safety | 12.6% | – |
| Growth | ||
| Revenue growth (TTM) | −1.9% | 9.7% (better) |
| Revenue growth, 5Y average | 16.9% (better) | −4.4% |
| Net income growth (TTM) | −49.9% | – |
| EPS growth (TTM) | −50.0% | – |
| Profitability | ||
| Gross margin | 63.9% (better) | 6.3% |
| Operating margin | 3.9% (better) | −13.2% |
| Net margin | 8.4% (better) | −14.5% |
| FCF margin | – | −8.9% |
| Return on equity | 13.3% (better) | −35.0% |
| Return on invested capital | 44.3% (better) | −25.2% |
| Financial health | ||
| Debt / equity | 0.00 | 0.20 (better) |
| Current ratio | 5.93 (better) | 1.73 |
| Altman Z-score | 3.87 (better) | 1.50 |
| Piotroski F-score | 7 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 3.4% (better) | 0.41% |
| Shareholder yield | 3.4% (better) | 0.41% |
| Ownership | ||
| Held by institutions | 40.4% | 10.5% |
| Held by insiders | 5.1% | 5.0% |
| Insider net buying, 12 months | $0 | $26.8K (better) |
| Short interest, % of float | 5.8% | 0.03% |
Go deeper
- NAGE stock overview
- NAGE income statement
- NAGE valuation and score
- NAII stock overview
- NAII income statement
- NAII valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.